Bristol-Myers Squibb: Phase III CheckMate-227, Part 1 study ESMO 2019 - 0 views
-
ramchintamaneni on 21 Oct 19Final data from BMS's Phase III CheckMate-227, Part 1 study was presented at the European Society of Medical Oncology conference in September.